Pityriasis rosea is a benign self-limiting rash, usually lasting 6 to 8 weeks. In classic pityriasis rosea a ‘herald patch’ is the initial finding, a large oval patch usually found on the torso. Smaller, scaly oval pink eruptions follow after 1 to 2 weeks on the chest, back and limbs, and can resemble a Christmas tree pattern on the back. It is seen more commonly in women, with a higher incidence in pregnancy, and has an estimated prevalence of around 1.3%. The rash usually heals without scarring and often no treatment is required. Symptomatic treatment is used occasionally to alleviate pruritus. This article will explore different presentations of pityriasis rosea, how to make a diagnosis and the main management options.
Get full access to this article
View all access options for this article.
References
1.
AhmedNIftikharNBashirU, et al. (2014)
Efficacy of clarithromycin in pityriasis rosea. Journal of the College of Physicians and Surgeons Pakistan24(11): 802–805. Available at: www.jcpsp.pk/archive/2014/Nov2014/05.pdf (accessed 6 March 2024).
2.
AshayerMMirnezamiMRahimiH (2018)
Pityriasis rosea in a mother and her daughter. A case report. Indian Dermatology Online Journal9(2): 131–132. DOI: 10.4103/idoj. IDOJ_135_17.
3.
AshforthGMYoussefSBhagavathiV, et al. (2023)
What’s old is new: Valacyclovir for the treatment of pityriasis rosea, a retrospective case series. Journal of the American Academy of Dermatology Case Reports37: 98–102. DOI: 10.1016/j.jdcr.2023.05.015.
4.
ChuhAZawarVSciallisG, et al. (2016)
A position statement on the management of patients with pityriasis rosea. Journal of the European Academy of Dermatology and Venereology30(10): 1670–1681. DOI: 10.1111/jdv.13826.
5.
DragoFBroccoloFZaccariaE, et al. (2008)
Pregnancy outcomes in patients with pityriasis rosea. Journal of the American Academy of Dermatology58(5 Suppl 1): S78–83. DOI: 10.1016/j.jaad.2007.05.030.
6.
DragoFCiccareseGReboraA, et al. (2016)
Pityriasis rosea: A comprehensive classification. Dermatology232(4): 431–437. DOI: 10.1159/000445375.
7.
DragoFVecchioFReboraA (2006)
Use of high-dose acyclovir in pityriasis rosea. Journal of the American Academy of Dermatology54(1): 82–85. DOI: 10.1016/j.jaad.2005.06.042.
8.
ErmertcanAOzguvenAErtanP, et al. (2010)
Childhood pityriasis rosea inversa without herald patch mimicking cutaneous mastocytosis. Iranian Journal of Paediatrics20(2): 237–241.
9.
HsuSLeEHKhoshevisMR (2001)
Differential diagnosis of annular lesions. American Family Physician64(2): 289–296. Available at: www.aafp.org/pubs/afp/issues/2001/0715/p289.html (accessed 6 March 2024)
10.
JairathVMohanMJindalN, et al. (2015)
Narrowband UVB phototherapy in pityriasis rosea. Indian Dermatology Online Journal6(5): 326–329. DOI: 10.4103/2229-5178.164480.
11.
KhanIElsanousiASharifA, et al. (2023)
Manifestation of pityriasis rosea and pityriasis rosea-like eruptions after covid-19 vaccine: A systematic review. Immunity, inflammation and Disease11(4): e804. DOI: 10.1002/iid3.804.
12.
LahouelISalahNAbdejlilN, et al. (2021)
A case series of pityriasis rosea-like adverse drug eruption. Health Science Journal15(8): 869.
13.
LawrenceEAl AboudK (2022) Postinflamamtory hyperpigmentation. Stat Pearls Publishing. October 2022.
14.
LimSKimSOhB, et al. (2009)
Low-dose ultraviolet A1 phototherapy for treating pityriasis rosea. Annals of Dermatology21(3): 230–236. DOI: 10.5021/ad.2009.21.3.230.
15.
LitchmanGNairPALeJK (2022) Pityriasis rosea. Stat Pearls Publishing, July 2022.
16.
MahajanKRelhanVRelhanA, et al. (2016)
Pityriasis rosea: An update on etiopathogenesis and management of difficult aspects. Indian Journal of Dermatology61(4): 375–384. DOI: 10.4103/0019-5154.185699.
PandaMPatroNJenaM, et al. (2014)
Pityriasis rosea like drug rash – a need to identify the disease in childhood. Journal of Clinical and Diagnostic Research8(8): YD01–YD02. DOI: 10.7860/JCDR/2014/8530.4652.
19.
PandhiDSingalAVermaP (2014)
The efficacy of azithromycin in pityriasis rosea: A randomized, double-blind, placebo-controlled trial. Indian Journal of Dermatology, Venereology and Leprology80(1): 36–40. DOI: 10.4103/0378-6323.125484.
20.
RasiATajziehchiLSavabi-NasabS (2008)
Oral erythromycin is ineffective in the treatment of pityriasis rosea. Journal of Drugs in Dermatology7(1): 35–38.
Rodriguez-ZunigaMTorresNGarcia-PerdomoH (2018)
Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis. Anais Brasileiros de Dermatologia93(5): 686–695. DOI: 10.1590/abd1806-4841.20187252.
23.
RycroftRJGRobertsonSJWakenSH (2010) Dermatology: A Color Handbook, 2nd edition.
▪▪▪:
Thieme Medical Publishers.
24.
SonthaliaSKumarAZawarV, et al. (2018)
Double-blind randomised placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea. The Journal of Dermatological Treatment29(6): 617–622. DOI:10.1080/09546634.2018.1430302.
25.
TzurLYangFDeverapalliS (2022)
The use of antivirals in severe or recalcitrant cases of pityriasis rosea: A case series. Journal of the American Academy of Dermatology Case Reports.
28:100–103. DOI: 10.1016/j.dcr.2022.05.032.
26.
UrbinaFDasASudyE (2017)
Clinical variants of pityriasis rosea. World Journal of Clinical Cases5(6): 203–211. DOI: 10.12998/wjcc.v5.i6.203.
27.
Villalon-GomezJM (2018)
Pityriasis rosea: Diagnosis and treatment. American Family Physician97(1): 38–44. Available at: from: www.aafp.org/pubs/afp/issues/2018/0101/p38.html (accessed 6 March 2024).
28.
Wenger-OehnLGraierTAmbros-RudolphC, et al. (2022)
Pityriasis in pregnancy: A case series and literature review. Journal of the German Society of Dermatology20(7): 953–959. DOI: 10.1111/ddg.14763.
